

CITATION REPORT

List of articles citing

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

DOI: 10.1016/j.clinthera.2006.11.015
Clinical Therapeutics, 2006, 28, 1779-802.

Source: <https://exaly.com/paper-pdf/39858320/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
428	Targeted therapies in small-cell lung cancer. 2007 , 11, 1033-41		2
427	Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. 2007 , 99, 1551-5		45
426	Pathological complete response in triple negative poorly differentiated invasive ductal breast carcinoma detected during pregnancy. 2007 , 25, 2618-20		8
425	Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. 2007 , 14, 348-53		87
424	Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. 2007 , 14, 468-80		27
423	Current world literature. 2007 , 20, 738-55		
422	Morphologic and functional imaging of malignant pleural mesothelioma. 2007 , 64, 356-66		64
421	The therapeutic potential of VEGF inhibition in diabetic microvascular complications. 2007 , 7, 393-8		23
420	Targeting cancer stem cells. 2007 , 11, 915-27		51
419	Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. 2007 , 6, 1275-83		45
418	Angiogenesis as targeted breast cancer therapy. 2007 , 16 Suppl 2, S17-9		39
417	Angiogenesis in melanoma. 2007 , 34, 555-65		105
416	S9 Blocking crosstalk between ER and growth factor receptors to circumvent endocrine resistance. 2007 , 16, S2-S3		
415	S10 Inflammation and breast cancer: Hypothesis for targeted therapies. 2007 , 16, S3		1
414	S11 Angiogenesis as targeted breast cancer therapy. 2007 , 16, S3		
413	S12 Immunity and breast cancer cells: Role of vaccination. 2007 , 16, S3-S4		
412	[Angiogenesis. Possibilities for therapeutic intervention in rheumatic diseases]. 2007 , 66, 304, 306-10		1

411	Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. 2007 , 133, 897-901	18
410	Development of the relationship between angiogenesis and tumor dormancy. 2007 , 4, 277-281	
409	Combining targeted therapies. 2007 , 2, 241-252	1
408	Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. 2008 , 89, 113-8	70
407	Glioblastoma multiforme. 2008 , 10, 285-94	7
406	MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. 2008 , 112, 17-26	149
405	Rapid construction of the cortistatin pentacyclic core. 2008 , 47, 6650-3	70
404	Rapid Construction of the Cortistatin Pentacyclic Core. 2008 , 120, 6752-6755	7
403	The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis. 2008 , 15, 49-64	30
402	Recent Advances in Angiogenesis Drug Development. 2008 , 421-430	
401	Hormone-refractory prostate cancer responding to bevacizumab. 2008 , 15, 754	4
400	Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer. 2008 , 9 Suppl 2, S51-6	
399	The diagnosis and management of cardiovascular disease in cancer patients. 2008 , 33, 163-96	48
398	Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens. 2008 , 12, 1250-5	10
397	Secondary hypertension: interfering substances. 2008 , 10, 556-66	30
396	Antiangiogenic effects of flavonoids and chalcones. 2008 , 57, 259-65	163
395	Thérapeutiques antiangiogéniques en cancérologie. 2008 ,	
394	Tumor Angiogenesis and the Cancer Stem Cell Model. 2008 , 249-258	1

393	Targeted Cancer Therapy. 2008 ,	6
392	Suppression of tumor-induced angiogenesis by taspine isolated from Radix et Rhizoma Leonticis and its mechanism of action in vitro. 2008 , 262, 103-13	35
391	Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. 2008 , 44, 1914-21	19
390	The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer. 2008 , 34, 231-46	9
389	Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. 2008 , 34, 378-90	247
388	Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. 2008 , 49, 902-9	9
387	Neurologic Complications of Chemotherapy. 2008 , 287-326	6
386	Angiogenesis. 2008 ,	25
385	Clinical approaches toward tumor angiogenesis: past, present and future. 2008 , 14, 3820-34	26
384	Advances in the systemic therapy of malignant pleural mesothelioma. 2008 , 5, 136-47	120
383	Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 2008 , 8, 717-32	8
382	Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. 2008 , 14, 7260-71	39
381	Osteonecrosis of the jaw related to bevacizumab. 2008 , 26, 4037-8	171
380	Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. 2008 , 7, 651-9	15
379	Intravitreal bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization overlying choroidal osteoma. 2008 , 2, 18-20	14
378	Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. 2008 , 27, 357-62	45
377	Bevacizumab: Review of Development, Pharmacology, and Application to Brain Tumors. 2009 , 1, CMT.S2042	
376	ESGCT, DGGT, GSZ, and ISCT 2009 Poster Presentations. 2009 , 20, 1417-1545	1

375	Statistical model to analyze quantitative proteomics data obtained by 18O/16O labeling and linear ion trap mass spectrometry: application to the study of vascular endothelial growth factor-induced angiogenesis in endothelial cells. 2009 , 8, 1130-49	54
374	Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: Initial results using a murine model. 2009 ,	
373	Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - preliminary results. 2009 ,	1
372	Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension. 2009 , 93, 837-8	16
371	Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. 2009 , 119, 3356-72	145
370	Bevacizumab-related osteonecrosis of the jaw. 2009 , 22, 1121-3	30
369	[Surgical management of bevacizumab-associated peritonitis due to perforation]. 2009 , 134, 462-7	6
368	Phase I and pharmacokinetic study of HER2-targeted rhuMab 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. 2009 , 39, 260-6	49
367	Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. 2009 , 27, 1069-74	244
366	The effect of panretinal photocoagulation for diabetic retinopathy on retinal nerve fibre layer thickness and optic disc topography. 2009 , 93, 838-9	10
365	Models for prevention and treatment of cancer: problems vs promises. 2009 , 78, 1083-94	117
364	The role of angiocidin in sarcomas. 2009 , 115, 5251-62	3
363	P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. 2009 , 117, 46-50	21
362	Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy. 2009 , 27, 41-52	9
361	Bowel perforation in non-small cell lung cancer after bevacizumab therapy. 2009 , 27, 184-7	25
360	Evaluation of hypertension as a marker of bevacizumab efficacy. 2009 , 40, 101-8	28
359	Non-invasive Monitoring of Angiogenesis in Cardiology. 2009 , 2, 59-66	6
358	Molecular imaging of cancer: evaluating characters of individual cancer by PET/SPECT imaging. 2009 , 100, 375-81	20

357	Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. 2009 , 12, 481-8	18
356	Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. 2009 , 16, 1619-28	58
355	Risk factors for massive blood transfusion in cytoreductive surgery: a multivariate analysis of 243 procedures. 2009 , 16, 2195-203	23
354	Multidisciplinary care for patients with breast cancer. 2009 , 89, 133-76, ix	21
353	Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. 2009 , 63, 264-70	52
352	Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. 2009 , 28, 35	7
351	A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. 2009 , 27, 141-54	18
350	Angiogenesis in adrenocortical physiology and tumor development. 2009 , 70, 153-5	8
349	Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis?. 2009 , 9, 182-8	40
348	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. 2009 , 114, 2149-58	162
347	Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. 2009 , 32, 508-12	22
346	Anti-cytokine therapeutics: history and update. 2009 , 15, 1998-2025	27
345	Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. 2010 , 33, 36-42	12
344	From Concept to the Clinics: Development of Novel Large Molecule Cancer Therapeutics. 2010 , 1	
343	Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. 2010 , 12, 592-601	30
342	Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression. 2010 , 17, 1945-56	42
341	Development of a novel homogenous electrochemiluminescence assay for quantitation of ranibizumab in human serum. 2010 , 52, 680-6	10
340	The effect of bevacizumab on colon anastomotic healing in rats. 2010 , 25, 1465-73	12

339	Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome. 2010 , 457, 11-9	20
338	Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. 2010 , 12, 521-5	9
337	Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. 2010 , 98, 427-30	6
336	Synthetic Strategies Directed Towards the Cortistatin Family of Natural Products. 2010 , 2010, 3553-3567	45
335	Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. 2010 , 163, 225-7	24
334	A Review of Docetaxel: Its Use in the Treatment of Gastric Cancer. 2010 , 2, CMT.S5191	
333	Microstatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. 2010 , 5, e10929	35
332	Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. 2010 , 29, 577-85	36
331	Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy. 2010 , 15, 011114	22
330	Bevacizumab. 2010 , 15, 819-25	115
329	Successful treatment of choroidal neovascularization complicating a choroidal osteoma with intravitreal bevacizumab. 2010 , 4, 303-5	7
328	Anti-tumour activity of fotemustine and protons in combination with bevacizumab. 2010 , 56, 214-22	4
327	Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. 2010 , 44, 1010-5	12
326	Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. 2010 , 2010, 814609	88
325	Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. 2010 , 9, 685-93	27
324	Overview of the Molecular Genetics and Molecular Chemotherapy of GBM. 2010 , 1-42	2
323	Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. 2010 , 16, 122-32	61
322	Bevacizumab: in previously treated glioblastoma. 2010 , 70, 181-9	18

3 ²¹	Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers. 2010 , 7, 41-8	25
3 ²⁰	Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. 2010 , 107, 12559-63	22
3 ¹⁹	Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. 2010 , 16, 3887-900	112
3 ¹⁸	Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. 2010 , 5, 181-92	33
3 ¹⁷	Cardiovascular effects of systemic cancer treatment. 2011 , 37, 300-11	147
3 ¹⁶	Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. 2011 , 37, 737-46	44
3 ¹⁵	Polyphyllin D, a steroidal saponin from Paris polyphylla, inhibits endothelial cell functions in vitro and angiogenesis in zebrafish embryos in vivo. 2011 , 137, 64-9	50
3 ¹⁴	Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma. 2011 , 21, 796-801	21
3 ¹³	Primary breast angiosarcoma: avoiding a common trap. 2011 , 2011, 517047	17
3 ¹²	Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with ⁶⁴ Cu-labeled bevacizumab in colorectal cancer xenografts. 2011 , 102, 117-21	49
3 ¹¹	Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. 2011 , 667, 153-9	39
3 ¹⁰	The biological basis for modern treatment of chordoma. 2011 , 104, 411-22	33
3 ⁰⁹	Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies. 2011 , 137, 1027-36	29
3 ⁰⁸	Anti-angiogenic therapy in glioma. 2011 , 13, 294-300	5
3 ⁰⁷	Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. 2011 , 29, 1525-30	155
3 ⁰⁶	Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. 2011 , 9, 629-46	28
3 ⁰⁵	Chemotherapy-induced cardiomyopathy. 2011 , 9, 231-43	9
3 ⁰⁴	Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study. 2012 , 28, 85-9	34

303	General and neurological complications of targeted therapy. 2012 , 105, 937-45	1
302	Target-based anti-angiogenic therapy in breast cancer. 2012 , 18, 4244-57	32
301	Bevacizumab as first-line therapy for glioblastoma. 2012 , 8, 929-38	5
300	Perfusion CT to assess angiogenesis in colon cancer: technical limitations and practical challenges. 2012 , 85, e814-25	11
299	Bevacizumab in endometrial cancer treatment. 2012 , 12, 649-58	14
298	Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. 2012 , 106, 1926-33	91
297	Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. 2012 , 17, 513-24	60
296	Stroma targeting nuclear imaging and radiopharmaceuticals. 2012 , 2012, 817682	3
295	Subdural hematoma in patients with cancer. 2012 , 71, 74-9	28
294	A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. 2012 , 120, 1210-7	51
293	Diaphragmatic rupture, a new complication of Bevacizumab. 2012 , 38, 1079-81	3
292	Drug-induced hypertension: an unappreciated cause of secondary hypertension. 2012 , 125, 14-22	166
291	Comparative binding of disulfide-bridged PEG-Fabs. 2012 , 23, 2262-77	52
290	Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. 2012 , 7, e35629	17
289	Vascular disrupting agent drug classes differ in effects on the cytoskeleton. 2012 , 7, e40177	18
288	Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. 2012 , 31, 1543-50	46
287	Synthesis and antiangiogenic activity of N-alkylated levamisole derivatives. 2012 , 7, e45405	7
286	Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. 2012 , 68, 1103-7	39

285	Antiangiogbiques: les anciens et les nouveaux. 2012 , 14, 216-225	
284	Role of chemotherapy in the management of vulvar carcinoma. 2012 , 82, 25-39	15
283	Osteonecrosis after administration of intravitreal bevacizumab. 2012 , 70, 632-5	32
282	A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. 2012 , 48, e2-3	33
281	A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. 2012 , 30, 490-507	9
280	Therapeutic antibodies: market considerations, disease targets and bioprocessing. 2013 , 440, 83-98	190
279	Positive association of the vascular endothelial growth factor-A +405 GG genotype and poor survival in stage I-II gastric cancer in the Northern Chinese population. 2013 , 40, 2741-8	8
278	Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. 2013 , 60, 580-6	45
277	Drug-induced thrombosis: an update. 2013 , 36, 585-603	36
276	Proliferation and maturation of intratumoral blood vessels in non-small cell lung cancer. 2013 , 44, 1586-96	30
275	A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. 2013 , 132, 2705-13	21
274	In vivo tumor detection using polarization and wavelength reflection characteristics of gold nanorods. 2013 , 13, 6292-6	27
273	Osteonecrosis of the mandible associated with bevacizumab therapy. 2013 , 115, e32-6	53
272	Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. 2013 , 31, 653-60	14
271	New approaches to treating primary effusion lymphoma. 2013 , 1, 1019-1029	4
270	Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors. 2013 , 31, e24-7	16
269	Rare and Unusual Forms of Hypertension. 2013 , 107-113	
268	Molecular/Targeted Therapy of Cancer. 2013 , 215-244	

267	Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951). 2013 , 9, 13-20	10
266	Novel drug discovery opportunities for colorectal cancer. 2013 , 8, 1153-64	17
265	Standardized added metabolic activity (SAM) IN 18 F-FDG PET assessment of treatment response in colorectal liver metastases. 2013 , 40, 1214-22	20
264	Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments. 2013 , 2013, 817279	4
263	Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor. 2013 , 54, 260-7	5
262	Novel cancer therapies: treatments driven by tumour biology. 2013 , 89, 652-8	14
261	Subconjunctival bevacizumab injection for ocular surface squamous neoplasia. 2013 , 32, 998-1001	20
260	Modeling efficacy of bevacizumab treatment for metastatic colon cancer. 2013 , 4, 330-5	9
259	Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. 2014 , 9, 43-53	9
258	Prognostic significance and targeting of HER family in colorectal cancer. 2013 , 18, 394-421	23
257	Emerging targeted combinations in the management of breast cancer. 2013 , 5, 61-72	3
256	Tratamiento de la retinopatía del prematuro con bevacizumab intravítreo. 2013 , 84, 300-307	1
255	Angiogenesis and its therapeutic opportunities. 2013 , 2013, 127170	274
254	Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI. 2014 , 9, e86583	21
253	Current status of treatment for primary effusion lymphoma. 2014 , 3, 65-74	76
252	Emerging biological treatments for uterine cervical carcinoma. 2014 , 5, 86-97	45
251	Therapeutic targeting of tumor angiogenesis: how far have we come?. 2014 , 4, 1113-1122	
250	The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. 2014 , 2014, 623759	85

249	Bevacizumab in the treatment of epithelial ovarian carcinoma. 2014 , 4, 535-548	
248	Imaging Angiogenesis. 2014 , 127-146	
247	Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?. 2014 , 15, 375	10
246	Vascular-targeted agents for the treatment of angiosarcoma. 2014 , 73, 259-70	19
245	6-Amino-2,4,5-trimethylpyridin-3-ols: a new general synthetic route and antiangiogenic activity. 2014 , 78, 126-39	26
244	The colon cancer stem cell microenvironment holds keys to future cancer therapy. 2014 , 18, 1040-8	28
243	Secondary arterial hypertension: when, who, and how to screen?. 2014 , 35, 1245-54	173
242	Pyridoxine-derived bicyclic amido-, ureido-, and carbamato-pyridinols: synthesis and antiangiogenic activities. 2014 , 12, 8702-10	6
241	Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols. 2014 , 24, 3131-6	11
240	(-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer. 2014 , 31, 625-33	25
239	Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients. 2015 , 6, 450-7	5
238	Neurosurgical Issues Related to Bevacizumab Use in the Management of Glioblastoma. 2015 , 25, 255-259	
237	Precision Subtypes of T Cell-Mediated Rejection Identified by Molecular Profiles. 2015 , 6, 536	3
236	Importance of serum VEGF and basic FGF levels in determining response to treatment and survival in patients with metastatic colorectal cancer. 2015 , 25, 24-31	
235	Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. 2015 , 358, 100-106	133
234	Targeting the tumor vasculature to enhance T cell activity. 2015 , 33, 55-63	169
233	Immunohistochemical expression of receptor tyrosine kinase PDGFR α -c-Met, and EGFR in skull base chordoma. 2015 , 38, 89-98; discussion 98-9	12
232	Novel benzoxazines as inhibitors of angiogenesis. 2015 , 33, 45-52	7

231	The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. 2015 , 104, 930-41	47
230	Preparation of multi-functionalized Fe ₃ O ₄ /Au nanoparticles for medical purposes. 2015 , 128, 1-7	19
229	Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review. 2015 , 214, 40-61	23
228	Storage stability of bevacizumab in polycarbonate and polypropylene syringes. 2015 , 29, 820-7	29
227	Drug induced hypertension--An unappreciated cause of secondary hypertension. 2015 , 763, 15-22	46
226	Implications of the Subquantum Level in Carcinogenesis and Tumor Progression via Scale Relativity Theory. 2015 ,	
225	Current opinion on bevacizumab on endometrial cancer treatment. 2015 , 15, 299-307	6
224	Overview of Epidemiology, Pathology, and Treatment of Primary Brain Tumors. 2015 , 11-28	2
223	Nanoemulsion in Drug Targeting. 2015 , 433-459	6
222	Recurrent hematuria in a patient with a previously undiagnosed transitional cell carcinoma of the right ureter after intravitreal bevacizumab (Avastin) injection: a case report. 2015 , 9, 45-6	1
221	Ocular surface squamous neoplasia: evidence for topical chemotherapy. 2015 , 55, 9-21	19
220	Uncovering a new role for peroxidase enzymes as drivers of angiogenesis. 2015 , 68, 128-38	20
219	Targeting cerebrovascular impairments in Huntington's disease: a novel treatment perspective. 2015 , 5, 389-93	4
218	Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. 2015 , 113, 1282-8	24
217	Prevention of recurrent pterygium with topical bevacizumab 0.05% eye drops: a randomized controlled trial. <i>Clinical Therapeutics</i> , 2015 , 37, 2347-51	3.5 14
216	Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. 2015 , 7, 1195-204	11
215	Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells. 2015 , 496, 1026-33	34
214	[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]. 2015 , 102, 906-14	2

213	K20E, an oxidative-coupling compound of methyl caffeate, exhibits anti-angiogenic activities through down-regulations of VEGF and VEGF receptor-2. 2015 , 282, 215-26	6
212	Immune effects of bevacizumab: killing two birds with one stone. 2015 , 8, 15-21	42
211	Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. 2015 , 141, 465-74	19
210	Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery. 2016 , 61, 249-259	21
209	Multimodality Targeting of Glioma Cells. 2016 , 55-72	
208	Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothed and GLI Inhibitors. 2016 , 8,	367
207	The Role of CC-Chemokines in the Regulation of Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3 57
206	Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Angiogenesis: Potential Clinical Application. 2016 , 7, 24	134
205	Serendipity in Cancer Drug Discovery: Rational or Coincidence?. 2016 , 37, 435-450	27
204	HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. 2016 , 19, 257-73	17
203	Advances in Cervical Cancer and Ongoing Clinical Trials. 2016 , 51-64	
202	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. 2016 ,	1
201	Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers. 2016 , 114, 196-201	9
200	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. 2016 , 130, 571-579	32
199	Overview of Pathology and Treatment of Primary Brain Tumors. 2016 , 9-22	
198	Gynecological Cancers. 2016 ,	
197	Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential. 2016 , 6, 36277	12
196	Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. 2016 , 95, e5392	14

195	Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?. 2016 , 10, 41-55	18
194	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of ⁸⁹ Zr-Bevacizumab PET Imaging in Brain Tumor Models. 2016 , 15, 2166-74	37
193	Remodeling the Vascular Microenvironment of Glioblastoma with Φ Particles. 2016 , 57, 1771-1777	20
192	Bevacizumab for the treatment of cervical cancer. 2016 , 16, 407-19	17
191	Patterns of prescribing radiotherapy and bevacizumab in nationwide practice - analysis of 101 designated cancer care hospitals in Japan. 2016 , 57, 157-63	1
190	Identifying Disease Associated miRNAs Based on Protein Domains. 2016 , 13, 1027-1035	13
189	A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. 2016 , 394, 197-211	16
188	Therapeutic interventions for aging: the case of cellular senescence. 2017 , 22, 786-795	113
187	Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. 2017 , 58, 215-219	8
186	Nasal septal perforation secondary to systemic bevacizumab. 2017 , 38, 354-355	7
185	Endothelial cell markers from clinician's perspective. 2017 , 102, 303-313	40
184	Cardio-Oncology. 2017 ,	1
183	Treatment of Hypertension in Patients Receiving Cancer Therapy. 2017 , 105-123	1
182	Molecular Markers for Colorectal Cancer. 2017 , 97, 683-701	18
181	VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. 2017 , 36, 5199-5211	49
180	Conformational latitude - activity relationship of KPPR tetrapeptide analogues toward their ability to inhibit binding of vascular endothelial growth factor 165 to neuropilin-1. 2017 , 23, 445-454	12
179	[Recent Developments Towards Molecularly Targeted Therapy of Head and Neck Cancer]. 2017 , 96, 185-198	
178	Gene delivery nanoparticles to modulate angiogenesis. 2017 , 119, 20-43	46

177	The Predictive Value of Early In-Treatment F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer. 2017 , 58, 1243-1248	13
176	Applications of high-resolution magic angle spinning MRS in biomedical studies I-cell line and animal models. 2017 , 30, e3700	20
175	Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. 2017 , 400, 243-251	18
174	3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. 2017 , 20, 629-640	14
173	Immunoliposomes: A review on functionalization strategies and targets for drug delivery. 2017 , 159, 454-467	94
172	Targeted Therapies. 2017 , 267-283	
171	Anti-angiogenic effect of seed extract and. 2017 , 14, 7565-7570	6
170	Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma. 2017 , 22, 1098-1115	6
169	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. 2017 ,	6
168	Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. 2017 , 1036, 191-211	11
167	A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3 90
166	An Optimal Control Approach for the Treatment of Solid Tumors with Angiogenesis Inhibitors. 2017 , 5, 49	13
165	Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3 45
164	Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. <i>Frontiers in Oncology</i> , 2017 , 7, 149	5.3 55
163	Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System. <i>Frontiers in Oncology</i> , 2017 , 7, 220	5.3 2
162	Nestin-positive microvessel density is an independent prognostic factor in breast cancer. 2017 , 51, 668-676	10
161	Biological agents in gastrointestinal cancers: adverse effects and their management. 2017 , 8, 485-498	20
160	The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. 2018 , 102, 1127-1144	27

159	Current and future management of recurrent respiratory papillomatosis. 2018 , 3, 22-34	59
158	Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis. 2018 , 137, 49-56	16
157	Positron Emission Tomography Imaging of Lung Cancer. 2018 , 219-232.e4	
156	Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. 2018 , 12, 87-94	5
155	Advances in organ preserving strategies in rectal cancer patients. 2018 , 44, 209-219	20
154	Antiangiogenic compounds: well-established drugs versus emerging natural molecules. 2018 , 415, 86-105	14
153	Luteolin inhibits angiogenesis of the M2-like TAMs via the downregulation of hypoxia inducible factor-1 α and the STAT3 signalling pathway under hypoxia. 2018 , 18, 2914-2922	13
152	Text mining-based drug discovery in cutaneous squamous cell carcinoma. 2018 , 40, 3830-3842	5
151	Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature. 2018 , 13, 422-427	7
150	Bevacizumab: A Rare Cause of Nonischemic Cardiomyopathy. 2018 , 2018, 1361326	0
149	Branched pentapeptides as potent inhibitors of the vascular endothelial growth factor 165 binding to Neuropilin-1: Design, synthesis and biological activity. 2018 , 158, 453-462	17
148	A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties. 2018 , 10, 1157-1167	22
147	Tumor Treatment. 2018 , 1219-1247	
146	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. 2018 , 116, 495-504	10
145	The Blood Vessel Wall. 2018 , 1843-1856.e6	1
144	Exosomes: mediators of bone diseases, protection, and therapeutics potential. 2018 , 5, 181-195	60
143	Water extract of Clinacanthus nutans leaves exhibits in vitro, ex vivo and in vivo anti-angiogenic activities in endothelial cell via suppression of cell proliferation. 2018 , 18, 210	6
142	A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis. 2018 , 6, 224	15

141	Establishment of an in ovo chick embryo yolk sac membrane (YSM) assay for pilot screening of potential angiogenic and anti-angiogenic agents. 2018 , 42, 1474-1483	14
140	Dual targeting delivery of miR-328 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. 2018 , 13, 1753-1772	23
139	Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer. 2019 , 43, 5-17	23
138	Endothelial capture using antibodies and nanoparticles in human tissues: Antigen identification and liver segment imaging. 2019 , 97, 474-489	3
137	Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions. 2019 , 93,	2
136	Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. 2019 , 154, 554-557	17
135	Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management. 2020 , 32, e1904337	61
134	Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature. 2019 , 13, 328	4
133	NIR-II Fluorescence Endoscopy for Targeted Imaging of Colorectal Cancer. 2019 , 8, e1900974	37
132	Targets for improving tumor response to radiotherapy. 2019 , 76, 105847	40
131	Cancer-associated adipocytes: key players in breast cancer progression. 2019 , 12, 95	128
130	Molecular Basis of Cisplatin Resistance in Testicular Germ Cell Tumors. 2019 , 11,	8
129	Mechanisms of Anti-angiogenic Therapy. 2019 , 183-208	
128	Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review. 2019 , 128, 467-471	9
127	TargetAntiAngio: A Sequence-Based Tool for the Prediction and Analysis of Anti-Angiogenic Peptides. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3 33
126	Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer. 2019 , 10, 1704-1715	13
125	Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of rapamycin/hypoxia-inducible factor 1 axis. 2019 , 110, 1724-1734	17
124	First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. 2019 , 12, 1095-1103	31

123	Approaches to Targeting Cancer Stem Cells in Solid Tumors. 2019 , 14, 421-427	3
122	Molecular/Targeted Therapy of Cancer. 2019 , 251-285	
121	Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10-year duration. 2019 , 33, 1225-1234	10
120	Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists. 2019 , 44, 1506-1519	8
119	Pharmacological and toxicological activities of the extracts of papaya leaves used traditionally for the treatment of diarrhea. 2020 , 32, 962-969	1
118	Convection enhanced delivery of anti-angiogenic and cytotoxic agents in combination therapy against brain tumour. 2020 , 141, 105094	9
117	Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review. 2020 , 36, 635-639	4
116	In Situ Visualization and SERS Monitoring of the Interaction between Tumor and Endothelial Cells Using 3D Microfluidic Networks. 2020 , 5, 208-216	7
115	Epidemiology of colorectal cancer. 2020 , 5-33	1
114	Tissue-engineered 3D cancer microenvironment for screening therapeutics. 2020 , 453-479	1
113	Vascular mimicry: Triggers, molecular interactions and in vivo models. 2020 , 148, 27-67	15
112	Clinical evaluation of plasma coagulation parameters in patients with advanced-stage non-small cell lung cancer treated with palliative chemotherapy in China. 2020 , 74, e13619	0
111	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. 2020 , 8, 584	16
110	Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma. 2020 , 10, 13659	22
109	Influences of Semaphorin 3A Expression on Clinicopathological Features, Human Papillomavirus Status, and Prognosis in Oropharyngeal Carcinoma. 2020 , 8,	0
108	Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: A double-masked, randomized trial. 2020 , 15, e0234186	3
107	Impact of Bevacizumab on Experimentally Induced Endometriotic Lesions: Angiogenesis, Invasion, Apoptosis, and Cell Proliferation. 2020 , 27, 1943-1950	3
106	Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China. <i>Frontiers in Oncology</i> , 2020 , 10, 800	53 5

105	Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. 2020 , 83, 937-954	11
104	Vestibular Schwannoma: What We Know and Where We are Heading. 2020 , 14, 1058-1066	8
103	Complex Dental Implant Complications. 2020 ,	
102	Update in the Treatment of Retinopathy of Prematurity. 2020 ,	3
101	Biosimilar monoclonal antibodies for cancer treatment. 2020 ,	0
100	In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer. 2020 , 10, 635-645	11
99	The Landscape of Targeted Therapies in TNBC. 2020 , 12,	92
98	Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. 2021 , 33, 490-499	0
97	Overview of monoclonal antibodies. 2021 , 1-29	0
96	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. 2021 , 13,	2
95	A 60% Edible Ethanolic Extract of Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis. 2021 , 26,	
94	HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with Wild Type Metastatic Colorectal Cancer. 2021 , 13,	4
93	Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. 2021 ,	7
92	Endoglin in the Spotlight to Treat Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 4
91	Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer. 2021 , 14, 101017	12
90	The evolution of commercial drug delivery technologies. 2021 , 5, 951-967	117
89	A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. 2021 , 153, 263-271	3
88	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. 2021 , 161, 374-381	4

87	New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis. 2021 , 13,	13
86	Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. 2021 , 1-10	2
85	Renal cell carcinoma therapy: Current and new drug candidates. 2021 , 27, 304-304	2
84	Surface Biomodification of Liposomes and Polymersomes for Efficient Targeted Drug Delivery. 2021 , 32, 1491-1502	6
83	Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications. 2021 , 26,	0
82	Evaluation of Integrin Expression in Murine Xenograft Models: [Ga]Ga-DOTA-C(RGDfK) PET Study with Immunohistochemical Confirmation. 2021 , 11,	
81	Anti-angiogenesis in cancer therapeutics: the magic bullet. 2021 , 33, 15	13
80	Cancer immunotherapy from biology to nanomedicine. 2021 , 336, 410-432	3
79	Review and comparative analysis of machine learning-based predictors for predicting and analyzing of anti-angiogenic peptides. 2021 ,	1
78	Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders. 2021 , 11,	4
77	Targeted Therapies for Breast Cancer Brain Metastases. 2021 , 21, 263-270	0
76	Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: A comprehensive review. 2021 , 7,	1
75	Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers. 2021 , 1,	0
74	Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy. 149-165	8
73	Revascularization of Wounds: The Oxygen-Hypoxia Paradox. 2008 , 541-559	1
72	Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. 2016 , 1386, 181-219	10
71	Vascular Endothelial Growth Factor (VEGF). 2016 , 363-374	1
70	Mechanisms of Anti-Angiogenic Therapy. 2017 , 1-25	2

69	Liver and Bile Duct Cancer. 2008 , 1569-1594	1
68	Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. 2012 , 2012,	14
67	Four common vascular endothelial growth factor polymorphisms (-2578C>A, -460C>T, +936C>T, and +405G>C) in susceptibility to lung cancer: a meta-analysis. 2013 , 8, e75123	10
66	Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. 2014 , 9, e91139	12
65	The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. 2017 , 8, 7666-7677	17
64	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. 2015 , 6, 5041-58	16
63	Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer. 2019 , 26, 5664-5683	7
62	2-(2-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth. 2017 , 17, 813-820	3
61	The Impact of Immune Cells on the Skeletal Muscle Microenvironment During Cancer Cachexia. 2020 , 11, 1037	12
60	Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. 2010 , 16, 3592-6	7
59	Neoadjuvant treatment of esophageal cancer. 2010 , 16, 3793-803	46
58	Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance. 2017 , 22, 117	36
57	Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. 2015 , 7, 1866-74	20
56	miR-155, miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers. 2020 , 46, 341-347	3
55	Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. 2011 , 2, 272-80	28
54	Anti-VEGF Therapy with Bevacizumab--limited cardiovascular toxicity. 2014 , 15, 10769-72	3
53	. 2011 , 2011, 1-5	1
52	From Concept to the Clinics: Development of Cancer Therapeutics.	

- 51 Postoperative and Preprosthetic Care. **2013**, 532-594
- 50 Endovascular Management of Tumors of the Head, Neck, and Spine. **2014**, 1-48
- 49 Endovascular Management of Tumors of the Head, Neck, and Spine. **2015**, 1-48
- 48 Endovascular Management of Tumors of the Head, Neck and Spine. **2015**, 2613-2653
- 47 Multi-targeted agents in the treatment of urothelial carcinoma. 353-361
- 46 Functionalized Gold Nanoparticles for Inhibition of Vascular Endothelial Growth Factor in Arthritic Patients. **2015**, 2,
- 45 Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK, and PK/PD of Therapeutic Biologics. 1-22 1
- 44 New Treatments and New Therapies. **2016**, 681-710
- 43 Vascular Normalization, T Cell Trafficking and Anti-tumor Immunity. **2016**, 51-76
- 42 Mechanisms of Anti-Angiogenic Therapy. **2017**, 1-25
- 41 Research on the Solution of Cell Invasion Model with Free Boundary. **2017**, 07, 242-261
- 40 Intralesional Bevacizumab (Avastin) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis. **2017**, 6, 190-191 3
- 39 A decade of targeted therapy for non-small cell lung cancer. **2017**, 1, 023-027
- 38 Primary ovarian cancer: possibilities for improving treatment outcomes. **2019**, 150-156 1
- 37 Monoklonal antikorlardan bevacizumab'ın deneysel inflamatuvar aB modelinde antianjiyogenik etkisi. 44, 33-40
- 36 Preventing and Treating Dental Implant Complications from Drugs Known to Cause Osteonecrosis of the Jaws. **2020**, 155-185
- 35 Accelerating bioactive peptide discovery via mutual information-based meta-learning. **2021**, 3
- 34 Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness. *International Journal of Molecular Sciences*, **2021**, 22, 6.3 3

33	Regression of Human Breast Carcinoma in Nude Mice After Adstft Gene Therapy is Mediated by Tumor Vascular Endothelial Cell Apoptosis.		
32	Targeted Drug Therapy in Pancreatic Cancer. 2008 , 271-287		
31	Les traitements antiangiogbiques modifient-ils l'histoire naturelle de la maladie en phase mEastasique?. 2008 , 183-195		
30	EfficacitDes antiangiogbiques dans le cancer du rein. 2008 , 105-122		
29	Durable, complete remission with bevacizumab-based chemotherapy in a patient with metastatic gastroesophageal junction cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2012 , 5, 177-8		1
28	Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovascularization. <i>International Journal of Ophthalmology</i> , 2013 , 6, 588-91	1.4	8
27	The Role of Wnt Signalling in Angiogenesis. <i>Clinical Biochemist Reviews</i> , 2017 , 38, 131-142	7.3	71
26	Single-dose Intravitreal Bevacizumab after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: an Effective Adjunctive Treatment. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2017 , 6, 76-81	1.4	4
25	Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2018 , 12, 136-141	0.5	6
24	Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options.. <i>Frontiers in Oncology</i> , 2021 , 11, 635737	5.3	0
23	Selecting patients for treatment with immunotherapy: Our experience in a resource-deprived economy. <i>International Journal of Immunotherapy and Cancer Research</i> , 2020 , 025-027	0.3	
22	AAPred-CNN: accurate predictor based on deep convolution neural network for identification of anti-angiogenic peptides.. <i>Methods</i> , 2022 ,	4.6	2
21	AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.. <i>Biomedicines</i> , 2022 , 10,	4.8	0
20	Data_Sheet_1.DOCX. 2018 ,		
19	The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 6911	6.3	1
18	The Role of the Microenvironment in Endometriosis: Parallels and Distinctions to Cancer. 2022 , 483-496		
17	COVID-19 and Blood Clots: Is it only The Virus to be Blamed? What are new Updates? A Systematic Review.		
16	Glioblastoma, from disease understanding towards optimal cell-based in vitro models. <i>Cellular Oncology (Dordrecht)</i> ,	7.2	1

15	An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia. <i>Experimental and Therapeutic Medicine</i> , 2022 , 24,	2.1	○
14	Hypertension in Cancer Survivors. <i>Current Hypertension Reports</i> ,	4-7	
13	Overview of pathology and treatment of primary brain tumours. 2022 , 9-24		○
12	Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: a review. 2022 , 57, 16192-16227		1
11	Single-cell sequencing reveals the cell map and transcriptional network of sporadic vestibular schwannoma. 15,		○
10	Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data. 2022 , 22,		○
9	Anti-hypoxic Agents for Improving Head and Neck Cancer Therapy. 2022 ,		○
8	Regression of Human Breast Carcinoma in Nude Mice after AdsfIt Gene Therapy Is Mediated by Tumor Vascular Endothelial Cell Apoptosis. 2022 , 14, 6175		○
7	Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. 2022 , 18, 755-767		○
6	Wnt3a is a promising target in colorectal cancer. 2023 , 40,		○
5	Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice. 2023 , 24, 3859		○
4	Septal perforations [state of the art. 2023 , 13, 2-10		○
3	Chorioallantoic membrane assay revealed the role of TIPARP (2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible poly (ADP-ribose) polymerase) in lung adenocarcinoma-induced angiogenesis. 2023 , 23,		○
2	A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab. 2023 , 11,		○
1	Targeted therapy. 2023 , 413-458		○